Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.

Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S, Garner G, Ayub M, Wood S, Rothwell DG, Fusi A, Wallace A, Brady G, Dive C, Dhomen N, Lorigan P, Marais R.

Ann Oncol. 2016 Oct;27(10):1959-65. doi: 10.1093/annonc/mdw278. Epub 2016 Aug 8.

2.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM Jr, Tarhini AA, Koon HB, Pecora AL, Jaslowski AJ, Cohen GI, Kuzel TM, Lao CD, Kirkwood JM.

Cancer. 2017 Jul 15;123(14):2688-2697. doi: 10.1002/cncr.30663. Epub 2017 Mar 23.

3.

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.

Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, Salari R, Kirkizlar E, Sigurjonsson S, Pelham R, Kareht S, Zimmermann B, Swanton C.

Ann Oncol. 2016 May;27(5):862-7. doi: 10.1093/annonc/mdw037. Epub 2016 Jan 28.

PMID:
26823523
4.

Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.

Rouzbahman M, Kamel-Reid S, Al Habeeb A, Butler M, Dodge J, Laframboise S, Murphy J, Rasty G, Ghazarian D.

J Low Genit Tract Dis. 2015 Oct;19(4):350-3. doi: 10.1097/LGT.0000000000000142.

PMID:
26225944
5.

Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.

Chicard M, Colmet-Daage L, Clement N, Danzon A, Bohec M, Bernard V, Baulande S, Bellini A, Deveau P, Pierron G, Lapouble E, Janoueix-Lerosey I, Peuchmaur M, Corradini N, Defachelles AS, Valteau-Couanet D, Michon J, Combaret V, Delattre O, Schleiermacher G.

Clin Cancer Res. 2018 Feb 15;24(4):939-949. doi: 10.1158/1078-0432.CCR-17-1586. Epub 2017 Nov 30.

6.

Tumour heterogeneity of mucosal melanomas during treatment with imatinib.

Schoenewolf NL, Urosevic-Maiwald M, Dummer R.

Br J Dermatol. 2011 Aug;165(2):419-24. doi: 10.1111/j.1365-2133.2011.10376.x.

PMID:
21495997
7.

Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.

Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, Kim K, Park W, Kim JH, Jang KT, Lee J.

Clin Transl Oncol. 2017 Oct;19(10):1247-1252. doi: 10.1007/s12094-017-1662-x. Epub 2017 Apr 18.

PMID:
28421416
8.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.

J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.

9.

Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.

Lyu J, Song Z, Chen J, Shepard MJ, Song H, Ren G, Li Z, Guo W, Zhuang Z, Shi Y.

J Pathol. 2018 Mar;244(3):358-366. doi: 10.1002/path.5017. Epub 2018 Feb 5.

PMID:
29230811
10.

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA.

Mol Cancer Ther. 2009 Aug;8(8):2079-85. doi: 10.1158/1535-7163.MCT-09-0459. Epub 2009 Aug 11.

11.

Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.

Murer C, Kränzlin-Stieger P, French LE, Dummer R, Goldinger SM.

Melanoma Res. 2017 Aug;27(4):396-398. doi: 10.1097/CMR.0000000000000358.

12.

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.

Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, Lee RJ, Garner G, Dhomen N, Lorigan PC, Marais R.

Eur J Cancer. 2018 Jan;88:1-9. doi: 10.1016/j.ejca.2017.10.029. Epub 2017 Nov 23.

13.

Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent.

Gleeson FC, Kerr SE, Kipp BR, Voss JS, Minot DM, Tu ZJ, Henry MR, Vasmatzis G, Cheville JC, Lazaridis KN, Levy MJ.

Gastrointest Endosc. 2016 Dec;84(6):950-958.e3. doi: 10.1016/j.gie.2016.04.027. Epub 2016 Apr 23.

PMID:
27118626
14.

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS.

Clin Cancer Res. 2008 Dec 1;14(23):7726-32. doi: 10.1158/1078-0432.CCR-08-1144.

15.

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.

Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, Rouleau E, Solary E, Soria JC, André F, Lacroix L.

PLoS One. 2017 Nov 21;12(11):e0188174. doi: 10.1371/journal.pone.0188174. eCollection 2017.

16.

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.

Gao J, Li J, Li Y, Li Z, Gong J, Wu J, Liu N, Dong B, Qi C, Li J, Shen L.

Oncotarget. 2016 May 24;7(21):30241-9. doi: 10.18632/oncotarget.7148.

17.

Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.

Calipel A, Landreville S, De La Fouchardière A, Mascarelli F, Rivoire M, Penel N, Mouriaux F.

Clin Exp Metastasis. 2014 Jun;31(5):553-64. doi: 10.1007/s10585-014-9649-2. Epub 2014 Mar 21.

PMID:
24652072
18.

Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.

Rapisuwon S, Parks K, Al-Refaie W, Atkins MB.

Melanoma Res. 2014 Oct;24(5):509-11. doi: 10.1097/CMR.0000000000000102.

PMID:
25003536
19.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.

Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, Park YS, Lim HY, Eltoukhy H, Kang WK, Lee WY, Kim HC, Park K, Lee J, Talasaz A.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.

20.

Lack of clinical efficacy of imatinib in metastatic melanoma.

Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, Schadendorf D.

Br J Cancer. 2005 Apr 25;92(8):1398-405.

Supplemental Content

Support Center